ASX:ILA

Island Pharmaceuticals (ILA) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.

ILA Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive ILA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Island Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-2,370,000.00
Net Margins
-247.34%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.37
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Paul Donald Richard MacLeman BVSc (Age 58)
    D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr, Executive Chairman
    Comp: $164.92k
  • Dr. David Charles Foster J.D.
    M.A.I.C.D., Ph.D., MD, CEO, President & Executive Director
  • Mr. Cameron Jones C.A.
    Joint Company Secretary
  • Stephanie Vipond
    Joint Company Secretary

This page (ASX:ILA) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners